---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-23-004058"
form_type: "8-K"
ticker: "ANIK"
cik: "0000898437"
company_name: "Anika Therapeutics, Inc."
filed_at: "2023-06-21T23:59:59+00:00"
generated_at: "2026-06-13T20:27:36.367523+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Anika appoints Anne Nunes as SVP, COO; shareholders approve 435K-share plan increase

## Summary
- Anne Nunes appointed SVP, Chief Operations Officer effective June 19, 2023; base salary $440,000, target bonus 45%.
- Stockholders approved amendment increasing 2017 Plan share reserve by 435,000 to 5,285,000 shares.
- Gary Fischetti, John Henneman, and Susan Vogt elected Class III directors until 2026 annual meeting.

## SEC filing metadata
- accession: 0001171843-23-004058
- form_type: 8-K
- ticker: ANIK
- cik: 0000898437
- company_name: Anika Therapeutics, Inc.
- filed_at: 2023-06-21T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/898437/000117184323004058/0001171843-23-004058-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/898437/000117184323004058/f8k_062123.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-23-004058
- JSON: https://secwatch.observer/filing/0001171843-23-004058.json
- Plain text: https://secwatch.observer/filing/0001171843-23-004058.txt

## Key facts
- Executive change
  Anne Nunes was appointed as Senior Vice President, Chief Operations Officer at Anika Therapeutics, Inc..
  - Action: appointed
  - Role: Senior Vice President, Chief Operations Officer
  source text: On June 14, 2023, the Board appointed Anne Nunes, age 54, as the Company’s Senior Vice President, Chief Operations Officer, effective as of June 19, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/898437/000117184323004058/0001171843-23-004058-index.htm
- Shareholder Votes
  Anika Therapeutics, Inc. shareholders approved Non-binding advisory vote to approve compensation of named executive officers at the 2023-06-14 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2023-06-14
  source text: Stockholders voted as follows with respect to this proposal: For Against Abstain Broker Non-Votes 11,873,054 227,519 51,162 1,168,309
  evidence_url: https://www.sec.gov/Archives/edgar/data/898437/000117184323004058/0001171843-23-004058-index.htm
- Shareholder Votes
  Anika Therapeutics, Inc. shareholders approved Ratification of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-14 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-06-14
  source text: Stockholders voted as follows with respect to this ratification proposal: For Against Abstain Broker Non-Votes 13,279,828 27,825 12,391 0
  evidence_url: https://www.sec.gov/Archives/edgar/data/898437/000117184323004058/0001171843-23-004058-index.htm
- Shareholder Votes
  Anika Therapeutics, Inc. shareholders approved Amendment to the 2017 Amended and Restated Stock Incentive Plan to increase authorized shares by 435,000 at the 2023-06-14 meeting.
  - Proposal: equity plan
  - Outcome: passed
  - Meeting: 2023-06-14
  source text: Stockholders voted as follows with respect to this proposal: For Against Abstain Broker Non-Votes 9,807,584 2,331,160 12,991 1,168,309
  evidence_url: https://www.sec.gov/Archives/edgar/data/898437/000117184323004058/0001171843-23-004058-index.htm
- Shareholder Votes
  Anika Therapeutics, Inc. shareholders approved Non-binding advisory vote on frequency of future advisory votes on executive compensation at the 2023-06-14 meeting.
  - Proposal: say on pay frequency
  - Outcome: passed
  - Meeting: 2023-06-14
  source text: Stockholders voted, on a non-binding, advisory basis, as follows with respect to the frequency of future advisory votes on compensation paid to the Company's named executive officers: 1 Year 2 Years 3 Years Abstain 11,078,317 3,067 1,038,679 31,672
  evidence_url: https://www.sec.gov/Archives/edgar/data/898437/000117184323004058/0001171843-23-004058-index.htm
- Shareholder Votes
  Anika Therapeutics, Inc. shareholders approved Election of three Class III directors at the 2023-06-14 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-06-14
  source text: Stockholders voted as follows with respect to election of each of the director nominees identified in the Proxy Statement: Nominee For Against Abstain Broker Non-Votes Gary P. Fischetti 12,032,739 106,519 12,477 1,168,309 John B. Henneman, III 11,054,795 1,079,499 17,441 1,168,309 Susan L. N. Vogt 11,721,294 417,401 13,040 1,168,309
  evidence_url: https://www.sec.gov/Archives/edgar/data/898437/000117184323004058/0001171843-23-004058-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.